Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Susceptible Staphylococcus aureus Infections – Pipeline Review, H1 2020, provides an overview of the Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline landscape.
Methicillin-Susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually cause skin infections, but can also cause pneumonia, and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea and abdominal pain. Predisposing factors include weakened immune systems, burns and surgical wounds.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Susceptible Staphylococcus aureus Infections – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 2, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.
Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Susceptible Staphylococcus aureus Infections – Pipeline Review, H1 2020, provides an overview of the Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline landscape.
Methicillin-Susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually cause skin infections, but can also cause pneumonia, and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea and abdominal pain. Predisposing factors include weakened immune systems, burns and surgical wounds.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Susceptible Staphylococcus aureus Infections – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 2, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.
Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development
Basilea Pharmaceutica Ltd
BioPlx Microbiomics Pvt Ltd
Debiopharm International SA
Destiny Pharma Plc
Galenus Therapeutics Inc
HyPharm GmbH
LegoChem Biosciences Inc
Naicons Srl
Sealife PHARMA GMBH
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drug Profiles
afabicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BioPlx-01KS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BioPlx-01WT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceftobiprole medocaril - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exeporfinium chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GTX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HY-133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LCB-010699 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAI-108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0904 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DNA Gyrase and DNA Topoisomerase IV for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
targocil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones
Featured News & Press Releases
Apr 20, 2018: Basilea reports presentations of ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Apr 12, 2018: Cardiome Presents Zevtera Abstracts at ECCMID 2018
Apr 21, 2017: Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development
Basilea Pharmaceutica Ltd
BioPlx Microbiomics Pvt Ltd
Debiopharm International SA
Destiny Pharma Plc
Galenus Therapeutics Inc
HyPharm GmbH
LegoChem Biosciences Inc
Naicons Srl
Sealife PHARMA GMBH
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drug Profiles
afabicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BioPlx-01KS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BioPlx-01WT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceftobiprole medocaril - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exeporfinium chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GTX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HY-133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LCB-010699 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAI-108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0904 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DNA Gyrase and DNA Topoisomerase IV for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
targocil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones
Featured News & Press Releases
Apr 20, 2018: Basilea reports presentations of ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Apr 12, 2018: Cardiome Presents Zevtera Abstracts at ECCMID 2018
Apr 21, 2017: Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Basilea Pharmaceutica Ltd, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by BioPlx Microbiomics Pvt Ltd, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Destiny Pharma Plc, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Galenus Therapeutics Inc, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by HyPharm GmbH, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by LegoChem Biosciences Inc, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Naicons Srl, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sealife PHARMA GMBH, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, H1 2020
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Basilea Pharmaceutica Ltd, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by BioPlx Microbiomics Pvt Ltd, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Destiny Pharma Plc, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Galenus Therapeutics Inc, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by HyPharm GmbH, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by LegoChem Biosciences Inc, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Naicons Srl, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sealife PHARMA GMBH, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, H1 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Basilea Pharmaceutica Ltd
BioPlx Microbiomics Pvt Ltd
Debiopharm International SA
Destiny Pharma Plc
Galenus Therapeutics Inc
HyPharm GmbH
LegoChem Biosciences Inc
Naicons Srl
Sealife PHARMA GMBH
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Basilea Pharmaceutica Ltd
BioPlx Microbiomics Pvt Ltd
Debiopharm International SA
Destiny Pharma Plc
Galenus Therapeutics Inc
HyPharm GmbH
LegoChem Biosciences Inc
Naicons Srl
Sealife PHARMA GMBH
